Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans
作者： Chia-Geun Chen , Yun-Liang Yang , Kuo-Yun Tseng , Hsin-I Shih , Ci-Hong Liou
DOI: 10.1016/J.FGB.2009.06.003
关键词: Corpus albicans 、 Drug resistance 、 Regulator 、 Saccharomyces cerevisiae 、 Efflux 、 Regulatory Pathway 、 Fluconazole 、 Candida albicans 、 Biology 、 Microbiology 、 Genetics
摘要: Overexpression of MDR1 efflux pump is a major mechanism contributing to drug resistance in Candida albicans, the most common human fungal pathogen. To elucidate regulatory pathway resistance, we have identified negative regulator and named it Regulator Efflux Pump 1 (REP1). REP1 Saccharomyces cerevisiae increased susceptibility fluconazole. Furthermore, null mutations on decreased antifungal drugs C. albicans resulting from expression mRNA. Hence, Rep1p involved by negatively regulating albicans.
nctu.edu.tw
elsevier.com参考文章(51)
Amanda M. Gillum, Emma Y. H. Tsay, Donald R. Kirsch, Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Molecular Genetics and Genomics. ,vol. 198, pp. 179- 182 ,(1984) , 10.1007/BF00328721
F.-M. C. Muller, Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis Journal of Antimicrobial Chemotherapy. ,vol. 46, pp. 338- 341 ,(2000) , 10.1093/JAC/46.2.338
Sarah Tsao, Fariba Rahkhoodaee, Martine Raymond, Relative Contributions of the Candida albicans ABC Transporters Cdr1p and Cdr2p to Clinical Azole Resistance Antimicrobial Agents and Chemotherapy. ,vol. 53, pp. 1344- 1352 ,(2009) , 10.1128/AAC.00926-08
S. P. Montano, M. L. Cote, I. Fingerman, M. Pierce, A. K. Vershon, M. M. Georgiadis, Crystal structure of the DNA-binding domain from Ndt80, a transcriptional activator required for meiosis in yeast Proceedings of the National Academy of Sciences of the United States of America. ,vol. 99, pp. 14041- 14046 ,(2002) , 10.1073/PNAS.222312199
M. A. Pfaller, D. J. Diekema, S. A. Messer, L. Boyken, R. J. Hollis, Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001 Journal of Clinical Microbiology. ,vol. 41, pp. 1440- 1446 ,(2003) , 10.1128/JCM.41.4.1440-1446.2003
Tim Joseph-Horne, Derek W Hollomon, Molecular mechanisms of azole resistance in fungi FEMS Microbiology Letters. ,vol. 149, pp. 141- 149 ,(1997) , 10.1111/J.1574-6968.1997.TB10321.X
David C. Lamb, Diane E. Kelly, Wolf-Hagen Schunck, Akbar Z. Shyadehi, Muhammed Akhtar, David J. Lowe, Brian C. Baldwin, Steven L. Kelly, The Mutation T315A in Candida albicans Sterol 14α-Demethylase Causes Reduced Enzyme Activity and Fluconazole Resistance through Reduced Affinity Journal of Biological Chemistry. ,vol. 272, pp. 5682- 5688 ,(1997) , 10.1074/JBC.272.9.5682
D Sanglard, F Ischer, M Monod, J Bille, Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrobial Agents and Chemotherapy. ,vol. 40, pp. 2300- 2305 ,(1996) , 10.1128/AAC.40.10.2300
T C White, Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial Agents and Chemotherapy. ,vol. 41, pp. 1482- 1487 ,(1997) , 10.1128/AAC.41.7.1482
Theodore C. White, Kieren A. Marr, Raleigh A. Bowden, Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clinical Microbiology Reviews. ,vol. 11, pp. 382- 402 ,(1998) , 10.1128/CMR.11.2.382